A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This trial is a follow-up companion study to Protocol ICA-17043-10, a Phase III,
multi-center, efficacy and safety study of ICA-17043. This is an open-label extension study
collecting safety data on the use of ICA-17043 in subjects with sickle cell disease (SCD)
(e.g., HbSS, HbSC, HbSb0-thalassemia, HbSb+-thalassemia subjects). All subjects who have
successfully completed ICA-17043-10 will, if deemed appropriate by their study Investigator
and appropriate consent by subject is given, enroll in the ICA-17043-12 study (Study 12).
Only patients who participated in ICA-17043-10 are eligible for this open label study
Phase:
Phase 3
Details
Lead Sponsor:
Icagen
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.